ArticleNature communications2021
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 2 pooled it
12.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- The Complex Role of Mast Cells in Head and Neck Squamous Cell Carcinoma: A Systematic Review.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.Journal of translational medicine · 2022Pooled it
- Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.Nature medicine · 2025Trial
- Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.Frontiers of medicine · 2023Trial
- Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.Nature communications · 2023Trial
- Article
- Preoperative tumor marker burden score predicts survival in colorectal cancer according to tumor size.BMC cancer · 2026Article
- The Tumor Multi-Omic Landscape of Endometrial Cancers Developed on a Background of Adiposity.Genes · 2026Article
- LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression.iScience · 2026Article
- ANKFN1 in skin fibroblasts may modulate mast cell activity and is associated with dupilumab response in atopic dermatitis.Immunologic research · 2026Article
- Loss of Mast cells and histaminergic signaling link diet to platelet-mediated NETosis and mammary cancer recurrence.bioRxiv : the preprint server for biology · 2026Article
- AllergoOncology: Emerging Translational and Clinical Significance of Basophils and Mast Cells in Cancer.Clinical and translational allergy · 2026Review
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
- Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships.Nature biomedical engineering · 2026Article
- Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Deciphering the Role of Mast Cells in HPV-Related Cancers.International journal of molecular sciences · 2025Review
- Bioinformatics driven in gene targeting platform for gold anticancer strategy delivery.Materials today. Bio · 2025Article
- Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer.Scientific reports · 2025Article
- Interactions Between Tryptase-Positive Mast Cells and Melanin-AInternational journal of molecular sciences · 2025Article
- Oligoclonal tumor-specific CD8 T-cell revival and IRE1α/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy in cervical cancer.Journal for immunotherapy of cancer · 2025Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
57 authors at 8 institutions in 3 countries.
Rajasekharan SomasundaramThe Wistar Institute, Philadelphia, PA, USA. Shyam@wistar.org.
Thomas ConnellyThe Wistar Institute, Philadelphia, PA, USA.
Robin ChoiThe Wistar Institute, Philadelphia, PA, USA.
Hyeree ChoiThe Wistar Institute, Philadelphia, PA, USA.
Anastasia SamarkinaThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0003-1553-4366
Ling LiThe Wistar Institute, Philadelphia, PA, USA.
Elizabeth GregorioThe Wistar Institute, Philadelphia, PA, USA.
Yeqing ChenThe Wistar Institute, Philadelphia, PA, USA.
Rohit ThakurDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Mohamed Abdel-MohsenThe Wistar Institute, Philadelphia, PA, USA.
Marilda BeqiriThe Wistar Institute, Philadelphia, PA, USA.
Meaghan KiernanThe Wistar Institute, Philadelphia, PA, USA.
Michela PeregoThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0002-5671-928X
Fang WangThe Wistar Institute, Philadelphia, PA, USA.
Min XiaoThe Wistar Institute, Philadelphia, PA, USA.
Patricia BraffordThe Wistar Institute, Philadelphia, PA, USA.
Xue YangThe Wistar Institute, Philadelphia, PA, USA.
Xiaowei XuDepartment of Pathology and Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Anthony SecretoDepartment of Medicine, Stem Cell and Xenograft Core, University of Pennsylvania, Philadelphia, PA, USA.
Gwenn Danet-DesnoyersDepartment of Medicine, Stem Cell and Xenograft Core, University of Pennsylvania, Philadelphia, PA, USA.
Daniel TraumDepartment of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Klaus H KaestnerDepartment of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alexander C HuangDepartment of Pathology and Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Denitsa HristovaThe Wistar Institute, Philadelphia, PA, USA.
Joshua WangThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0002-9949-798X
Mizuho Fukunaga-KalabisThe Wistar Institute, Philadelphia, PA, USA.
Clemens KreplerThe Wistar Institute, Philadelphia, PA, USA.
Fang Ping-ChenThe Wistar Institute, Philadelphia, PA, USA.
Xiangyang ZhouThe Wistar Institute, Philadelphia, PA, USA.
Alexis GutierrezThe Wistar Institute, Philadelphia, PA, USA.
Vito W RebeccaThe Wistar Institute, Philadelphia, PA, USA.
Prashanthi VontedduThe Wistar Institute, Philadelphia, PA, USA.
Farokh DotiwalaThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0002-7387-2219
Shashi BalaThe Wistar Institute, Philadelphia, PA, USA.
Sonali MajumdarThe Wistar Institute, Philadelphia, PA, USA.
Harsh DweepThe Wistar Institute, Philadelphia, PA, USA.
Jayamanna WickramasingheThe Wistar Institute, Philadelphia, PA, USA.
Andrew V KossenkovThe Wistar Institute, Philadelphia, PA, USA.
Jorge Reyes-ArbujasThe Wistar Institute, Philadelphia, PA, USA.
Kenisha SantiagoThe Wistar Institute, Philadelphia, PA, USA.
Tran NguyenThe Wistar Institute, Philadelphia, PA, USA.
Johannes GrissDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2206-9511
Frederick KeeneyThe Wistar Institute, Philadelphia, PA, USA.
James HaydenThe Wistar Institute, Philadelphia, PA, USA.
Brian J GavinThe Wistar Institute, Philadelphia, PA, USA.
David WeinerThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0002-2232-8512
Luis J MontanerThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-5799-6759
Qin LiuThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-9964-580X
Lukas PeifferUniversity of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-3729-2249
Jürgen BeckerUniversity of Duisburg-Essen, Essen, Germany.
Elizabeth M BurtonDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, University of California, San Francisco, CA, USA.ORCID 0000-0002-0977-0912
Michael T TetzlaffDepartment of Pathology and Dermatology, University of California, San Francisco, CA, USA.
Kar MuthumaniThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0002-6807-2065
Jennifer A WargoDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3438-7576
Dmitry GabrilovichAstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0001-9913-6407
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA. Herlynm@wistar.org.
The Wistar Institute · USUniversity of Pennsylvania · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Duisburg-Essen · DEAstraZeneca (United States) · USMedical University of Vienna · ATNational Cancer Institute · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Meenhard F Herlyn · 2017 to 2026
$13.9MRole of Runx2 in prostate tumorigenesis and metastasisP01CA140043 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2010 to 2021
$12.2MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MLipids and Myeloid Cell Function in CancerR01CA165065 · NCI · WISTAR INSTITUTE · PI KAGAN, VALERIAN E, MONTANER, LUIS J · 2012 to 2022
$3.8MIntegrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6MNCI NIH HHS P01 CA114046NCI NIH HHS P01 CA140043NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA165065NCI NIH HHS R50 CA211199NCI NIH HHS U54 CA224070
Abstract
Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by injecting fetal liver-derived CD34
Indexed as
Drug Resistance, NeoplasmAnimalsB-LymphocytesHumansImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMast CellsMelanomaMice, TransgenicProgrammed Cell Death 1 ReceptorSunitinibT-LymphocytesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorSunitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.